News | 16 August 2012
NEW YORK Aug 16 (Reuters Breakingviews) - The U.S. pharmaceutical industry can't sugarcoat its generic drug deals any longer. Pfizer's Wyeth unit is the latest company to sustain its monopoly over a patented medication by handing a rival exclusive, but ...
Click on the link to read the full article at Reuters
(This link will open in a new window)